ALLMedicine™ Acneiform Eruptions Center

Sep 8th, 2021 - Background and Study Aims: Tyrosine Kinase inhibitors (TKIs) have become standard of care in patients with EGFR mutations in non-small cell lung cancer and other EGFR-mutated cancers. However, TKIs are well-known to cause cutaneous adverse events,...

Apr 22nd, 2021 - Two adolescent boys presented with acute acneiform eruptions in the setting of recent dupilumab administration. Subsequent investigation via direct scraping of pustules revealed live Demodex mite colonization of the face. These adolescent patients...

Apr 21st, 2021 - Programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors have demonstrated their efficacy in the treatment of various malignancies. Despite their benefits, their immunomodulatory activities can cause unpredictable cutaneous adverse e...

Mar 9th, 2021 - The most common adverse event of epidermal growth factor receptor inhibitors, used to treat colorectal, non-small cell lung, and head and neck cancers, is acneiform eruption, with a profound effect on treatment continuation. Prolonged acneiform er...

Jan 29th, 2021 - Epidermal growth factor receptor (EGFR) inhibitors are routinely used in advanced non-small-cell lung cancer (NSCLC) harboring EGFR mutations. However, their use is associated with gastrointestinal and cutaneous toxicities, including acneiform eru...

Sep 8th, 2021 - Background and Study Aims: Tyrosine Kinase inhibitors (TKIs) have become standard of care in patients with EGFR mutations in non-small cell lung cancer and other EGFR-mutated cancers. However, TKIs are well-known to cause cutaneous adverse events,...

Jul 30th, 2020 - NEW YORK (Reuters Health) - Skin reactions are common in youngsters on MEKI/BRAFI therapy, often resulting in alterations or interruptions in cancer therapy, according to a multicenter retrospective study. "Every child in our study developed at le...

Dec 22nd, 2015 - The most common skin toxicities associated with epidermal growth-factor receptor tyrosine kinase inhibitors (EGFR-TKIs), which are used in the treatment of non-small-cell lung cancer (NSCLC), are acne-like lesions, itching, dry skin, and nail bed ...

Jan 1st, 2013 - HISTORY This 40-year-old man was urged by his wife to consult dermatology about a lesion he first noted on his left flank when he was 12. Since then, it has grown darker and more hairy but otherwise has not changed.

No abstract available.

Ablative fractional resurfacing appears to be safe and effective in Asians with mild to moderate atrophic acne scarring, according to a study of 13 patients. While 12 of the 13 patients experienced some postinflammatory hyperpigmentation, this res.